New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
15:26 EDTNYCB, DELL, CELG, EXPR, GMCRStocks with expanding option implied volatility; EXPR DELL GMCR CELG NYCB
News For EXPR;DELL;GMCR;CELG;NYCB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 9, 2016
12:32 EDTGMCROptions with decreasing implied volatility
Options with decreasing implied volatility: VHC APOL SRPT GRUB BWLD DECK UBNT GMCR
February 8, 2016
14:01 EDTGMCREarnings Watch: Analysts becoming more positive on Coca-Cola
Subscribe for More Information
10:13 EDTGMCROptions with decreasing implied volatility
Subscribe for More Information
February 7, 2016
20:36 EDTCELGOn The Fly: Top five weekend stock stories
Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Ford (F) plans to build a new assembly plant in Mexico and expand its existing factory near Mexico City, sharply increasing production capacity in the country as it looks to focus its U.S. efforts on trucks and SUVs, the Wall Street Journal reported. 2. GoPro (GPRO) and Microsoft (MSFT) signed a patent licensing agreement late Friday, lifting shares of the action camera maker in after-hours trading. 3. Media reports indicate Twitter (TWTR) could be rethinking its news feed, potentially ordering posts based on popularity rather than chronological date. 4. Apollo Education (APOL) received a second investigative subpoena from California's attorney general related to the marketing, recruiting, accreditation, and other aspects of its for-profit schools. 5. Celgene (CELG), Gilead (GILD), Thermo Fisher (TMO) and Vantiv (VNTV) were mentioned positively by Barron's this weekend, while Church & Dwight (CHD) was called overvalued and GoPro was identified as a possible takeover target by Under Armour (UA) or Sony (SNE).
12:38 EDTCELGCelgene, Gilead too cheap to ignore, could rise 30% in next year, Barron's says
Shares of Celgene (CELG) and Gilead (GILD) could advance 30% over the next year, Barron's contends in a feature article. Concerns over the two firms having too much revenue concentrated in just a few key products are legitimate but "solvable," and their shares now look "too cheap to ignore" amid the general rout in biotech names, the publication says. Reference Link
February 5, 2016
11:14 EDTNYCBOptions with increasing call volume
Subscribe for More Information
09:26 EDTCELGLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:04 EDTCELGCelgene resumed with a Market Perform at Leerink
Subscribe for More Information
February 4, 2016
16:37 EDTCELGCelgene reinitiated with a Market Perform at Leerink
Subscribe for More Information
10:36 EDTCELGCelgene February weekly calls activity attributed to takeover speculation
Subscribe for More Information
10:31 EDTCELGRumor: Celgene strength attributed to takeover speculation
Shares of Celgene (CELG) are moving higher amid renewed speculation Bristol-Meyers (BMY) is interested in acquiring the company.
10:10 EDTGMCROptions with decreasing implied volatility
Subscribe for More Information
07:56 EDTGMCRSONIC, Keurig Green Mountain announce coffee partnership
Subscribe for More Information
February 3, 2016
08:57 EDTCELGPullback in biotech makes M&A more attractive, says UBS
UBS analyst Andrew Peters noted the pullback in small and mid-cap biotechs and said a consequence of the lower valuations may be an increased appetite for M&A by the larger firms. Peters noted Gilead (GILD) commented on its earnings call that "there's no question" the pullback has made M&A more attractive. UBS said with valuations so far off their highs, the question remains whether management and boards will accept deals at such depressed levels.
February 2, 2016
10:32 EDTNYCBNew York Community Bancorp management to meet with Sandler O'Neill
Meeting to be held in New York on February 3 hosted by Sandler O'Neill.
08:53 EDTCELGPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
08:19 EDTGMCRKeurig Green Mountain will not be issuing Q1 earnings or updating guidance
As previously disclosed, on December 6, 2015, Keurig Green Mountain entered into an Agreement and Plan of Merger by and among Acorn Holdings B.V., a private limited liability company incorporated under the laws of the Netherlands, Maple Holdings Acquisition Corp.. Due to the pending Merger, the company is neither updating nor reaffirming its prior earnings guidance, and will not be issuing a fiscal first quarter 2016 earnings release or holding a fiscal first quarter 2016 earnings call for investors and financial analysts.
January 29, 2016
12:24 EDTGMCRCitron sees Monster Beverage shares hitting $80 in near term
Shares of Monster Beverage (MNST) are likely to hit $80 in the near term, Citron Research writes in a new research report on the energy drink maker. The short-selling research firm says valuing Monster versus Dr Pepper Snapple (DPS) results in 48% downside for the stock. "For the sake of the benefit of the doubt we used the post GMCR takeout value as a benchmark to get to $80 a share for Monster," Citron states. Monster shares are down $7.15, or 5%, to $130.05 in midday trading. Reference Link
08:17 EDTCELGCelgene fundamentals, valuation compelling, says Cantor
Cantor says that Celgene's sell-off was not caused by its results, but by other factors such as currency fluctuations. The firm says that the company's EPs growth remains strong, while its pipeline can enable the company to keep growing over the longer term. The firm continues to expect the company to generate strong cash flow, and it reiterates a $163 price target and Buy rating on the shares.
08:06 EDTCELGUBS said no change to bullish stance on Celgene
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use